Non-complement–binding de novo donor-specific anti-HLA antibodies and kidney allograft survival

G Guidicelli, F Guerville, S Lepreux… - Journal of the …, 2016 - journals.lww.com
C1q-binding ability may indicate the clinical relevance of de novo donor-specific anti-HLA
antibodies (DSA). This study investigated the incidence and risk factors for the appearance
of C1q-binding de novo DSA and their long-term impact. Using Luminex Single Antigen
Flow Bead assays, 346 pretransplant nonsensitized kidney recipients were screened at 2
and 5 years after transplantation for de novo DSA, which was followed when positive by a
C1q Luminex assay. At 2 and 5 years, 12 (3.5%) and eight (2.5%) patients, respectively, had …